How male and female biology changes antibody control of blood vessel growth
Mechanistic basis of sexual dimorphism in antigen-independent IgG1 angiogenesis regulation
This research looks at why male and female biology changes how IgG1 antibodies control blood vessel growth, which could matter for conditions like Alzheimer's, heart disease, stroke, and eye disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project ID | NIH-11293438 on NIH RePORTER |
What this research studies
Researchers will compare sex-linked factors — both sex chromosomes and sex hormones — to see how they change antibody-driven suppression of new blood vessel growth. They will test whether a Y chromosome gene called DDX3Y explains stronger antibody angio-inhibition seen in males. The work combines laboratory models with experiments in human cells. The team will also measure the same sex-related effects in human tissue or blood samples to link the lab findings to people.
Who could benefit from this research
Good fit: Ideal candidates would be adults with conditions involving abnormal blood vessel growth (for example Alzheimer's-related vascular changes, heart disease, stroke, or macular degeneration) who are willing to provide blood or tissue samples.
Not a fit: People with conditions unrelated to blood vessel growth or those seeking immediate clinical treatment are unlikely to receive direct benefit from this basic-mechanism research.
Why it matters
Potential benefit: If successful, this work could point to sex-specific targets for controlling abnormal blood vessel growth and eventually lead to better, more personalized treatments for diseases influenced by angiogenesis.
How similar studies have performed: This area is relatively new: prior preliminary data show sex differences in antibody-driven angio-inhibition, but mechanistic work on DDX3Y and translating it to human samples is novel and early-stage.
Where this research is happening
Charlottesville, United States
- University of Virginia — Charlottesville, United States (Active)
Researchers
- Principal investigator: Gelfand, Bradley David — University of Virginia
- Study coordinator: Gelfand, Bradley David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.